Skip to Content
 
 
 
 

ULI-EAP-100 (BVD-523): EXPANDED ACCESS TO ULIXERTINIB (BVD-523) IN PATIENTS WITH ADVANCED MAPK PATHWAY-ALTERED MALIGNANCIES

Objective

Clinical Trial Details

Principal Investigator(s)
Houman Nourkeyhani, MD

Clinical Trial Categories

  • Brain Cancer
  • Colorectal Cancer
  • Hepatocellular/Liver Cancer
  • Pancreatic Cancer
  • Lung Cancer
  • Renal/Urinary Tract Cancer
  • Head and Neck Cancer
  • Prostate Cancer
  • Esophageal/Gastroesophageal Junction (GEJ)
Contact
Medical Oncology Research Coordinators at 605-322-3295
or medoncresearch@avera.org

Location

  • Avera Cancer Institute at Sioux Falls
    1000 E. 23rd Street
    Sioux Falls, SD 57105
    Main: 605-322-3000
    Alternate: 800-657-4377

Moving Health Forward

Avera is a health ministry rooted in the Gospel. Our mission is to make a positive impact in the lives and health of persons and communities by providing quality services guided by Christian values.

© 2022 Avera Health, Sioux Falls, SD. All Rights Reserved.